Atypical lobular hyperplasia on core needle biopsy: contemporary results from a large community hospital breast program

Breast Cancer Res Treat. 2020 Oct;183(3):771-774. doi: 10.1007/s10549-020-05799-9. Epub 2020 Jul 23.

Abstract

Purpose: The management of biopsy proven atypical lobular hyperplasia (ALH) is controversial. Although upgrade rates are low, excisional biopsy is often performed to rule out occult breast cancer.

Methods: In this study, we analyzed our experience with excisional biopsy for ALH diagnosed in the digital tomosynthesis era with radiographic concordance in the community hospital setting. This study included 93 consecutive patients diagnosed with pure ALH on core biopsy from January 2013-December 2017 who underwent subsequent excisional biopsy. Potential clinical, radiographic and pathologic predictors of upgrading were analyzed.

Results: At the time of excisional biopsy, five patients (5.4%) were upgraded to DCIS or invasive breast cancer. There was also a trend towards higher upgrade rates in patients with contralateral breast cancer (p = 0.06), biopsy performed by ultrasound or MRI (p = 0.07) and extensive ALH (p = 0.10). Other clinical, radiographic and pathologic variables were not predictive of upgrade rate (p > 0.1 for all).

Conclusion: Patients with pure ALH with radiographic concordance have a low risk of pathologic upgrading on excisional biopsy. Potential predictors of upgrade rate warrant further analysis in a larger dataset.

Keywords: Atypical lobular hyperplasia; Core needle biopsy; Excisional biopsy; Upgrade rate.

MeSH terms

  • Biopsy, Large-Core Needle
  • Breast / diagnostic imaging
  • Breast / pathology
  • Breast / surgery
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / pathology
  • Carcinoma in Situ* / pathology
  • Carcinoma, Lobular* / diagnostic imaging
  • Carcinoma, Lobular* / epidemiology
  • Female
  • Hospitals, Community
  • Humans
  • Hyperplasia / pathology